30 May 2019


Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

The table below provides further detail.

 

Name of company: Futura Medical plc

Name of scheme(s): Unapproved Share Option Scheme ("USOS") Unapproved Share Incentive Scheme ("USIS") EMI Share Option Scheme ("EMI")

Period of return: From: 1 December 2018

To: 30 May 2019

Number and class of securities not issued under the scheme(s) at beginning of period USOS: 1,993,875

USIS: 425,000

EMI: 3,806,125

Total: 6,225,000

Number and class of securities admitted to the scheme(s) in the period USOS: -

USIS: -

EMI: -

Total: -

Number of securities issued under the scheme(s) during the period USOS: -

USIS: -

EMI: -

Total: -

Number of securities lapsed under the scheme(s) during the period USOS: -

USIS: -

EMI: -

Total: -

Balance of securities under the scheme(s) not yet issued at the end of the period USOS: 1,993,875

USIS: 425,000

EMI: 3,806,125

Total: 6,225,000




 
Number and class of securities originally admitted and the date of admission USOS:
814,424 25 May 2011,
1,202,280 8 October 2013,
1,466,208 25 May 2017,
400,000 30 May 2018,
USOS Total: 3,882,912

USIS:
425,000 30 November 2018

USIS Total: 425,000

EMI:
1,520,576 25 May 2011,
1,467,720 8 October 2013,
1,893,792 25 May 2017,
790,000 30 May 2018,
1,340,000 30 November 2018


EMI Total: 7,012,088





Total: 11,320,000









For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670

Liberum (Nominated Adviser and Broker)
Bidhi Bhoma
Euan Brown
Kane Collings
Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com